|Bid||53.80 x 900|
|Ask||55.25 x 1100|
|Day's Range||53.90 - 55.40|
|52 Week Range||36.65 - 136.90|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2018 - Aug 13, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||96.00|
NEW YORK, NY / ACCESSWIRE / May 16, 2018 / U.S. markets slumped Tuesday, with the Dow Jones breaking an 8-day win streak, as interest rates surged to new highs. The Dow Jones Industrial Average declined 0.78 percent to close at 24,706.41, while the S&P 500 Index fell 0.68 percent to close at 2,711.45.
NEW YORK, NY / ACCESSWIRE / May 11, 2018 / Puma Biotechnology shares sank on Thursday after it revealed concerning information about Nerlynx, a prescription medicine used to treat adults who have early-stage breast cancer, as well as its first quarter earnings. Puma Biotechnology, Inc. shares closed down 20.67% on almost 5.5 million shares traded yesterday.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2018.
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:40 a.m. PDT on Wednesday, May 16, at the Bank of America Merrill Lynch Health Care Conference 2018. Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. The Company in-licenses the global development and commercialization rights to three drug candidates — PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.
On the Q1 call, investor focus will be on sales of Puma Biotechnology's (PBYI) only marketed product, Nerlynx and updates on other label expansion studies on the drug.
NEW YORK, NY / ACCESSWIRE / April 30, 2018 / U.S. equities were mixed Friday as strong earnings reports from major companies failed to boost investor's enthusiasm. The Dow Jones Industrial Average dropped ...
Puma Biotechnology, Inc. (PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Wednesday, May 9, 2018 following release of its first quarter 2018 financial results. Please dial in at least ten minutes in advance and inform the operator that you would like to join the “Puma Biotechnology Conference Call.” A live webcast of the conference call and presentation slides may be accessed on the Investors section of the Puma Biotechnology website at http://www.pumabiotechnology.com. A replay of the call will be available approximately one hour after completion of the call and will be archived on the Company's website for 90 days.
Puma Biotechnology, Inc. , a biopharmaceutical company, and Pint Pharma International S.A., a company focused on innovative treatments for patients in Latin America with cancer, rare diseases, and genetic disorders, have entered into an agreement for Pint Pharma to commercialize NERLYNX® in Argentina, Brazil, Chile, Colombia, Mexico and the rest of Latin America.
Although the FDA approval for Puma's (PBYI) Nerlynx along with strategic alliances appreciates the stock in 2017, the CHMP's negative opinion on the cancer drug in 2018 affects its share price.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced today that NERLYNX® has been included as a recommended treatment option in the latest National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology Central Nervous System Cancers for Breast Cancer patients with brain metastases.
Puma Biotechnology (PBYI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
The following statement is being issued by Robbins Geller Rudman & Dowd LLP regarding the Puma Biotechnology, Inc. Litigation:
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 11:20 a.m.
Puma (PBYI) posts narrower-than-expected loss in Q4. Revenues also surpass estimates supported by sales of the company's only marketed drug, Nerlynx.
Puma Biotechnology, Inc. , a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2017. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2017, compared to the fourth quarter and full year 2016.
NEW YORK, NY / ACCESSWIRE / March 1, 2018 / Puma Biotechnology, Inc. (NASDAQ: PBYI ) will be discussing their earnings results in their Q4 Earnings Call to be held on March 1, 2018 at 4:30 PM Eastern Time. ...
Stock Monitor: BioMarin Pharma Post Earnings Reporting LONDON, UK / ACCESSWIRE / February 27, 2018 / Active-Investors.com has just released a free research report on Puma Biotechnology, Inc. (NASDAQ: PBYI ...
KemPharm, Inc. (NASDAQ:KMPH) ran into the end of last week on news related to the company’s lead development program. At the close of trade on Friday, KemPharm shares were going for around six dollars apiece, up more than 13% on the day’s open. Premarket on Monday, shares rose again to $6.35 but have since settled […] The post Here’s What’s Moving KemPharm And Puma Biotechnology appeared first on Market Exclusive.
Puma Biotechnology, Inc. announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has adopted a negative opinion, recommending the refusal of the Marketing Authorisation Application for neratinib for the extended adjuvant treatment of early stage HER2-positive breast cancer.
NEW YORK, Feb. 20, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of SunCoke ...
Puma Biotechnology, Inc. , a biopharmaceutical company, will host a conference call at 1:30 p.m. PST/4:30 p.m. EST on Thursday, March 1, 2018 following release of its fourth quarter and full year 2017 financial results.
NEW YORK, NY / ACCESSWIRE / February 15, 2018 / U.S. markets rallied sharply from early losses Wednesday as inflation fears appear to be easing on Wall Street. The Dow Jones Industrial Average jumped 1.03 ...
Puma Biotechnology, Inc. , a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 3:30 p.m.